Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Ziprasidone (Higher Dose)	232
Overall Study	STARTED	Ziprasidone (Lower Dose)	226
Overall Study	STARTED	Placebo	222
Overall Study	Received Study Treatment	Ziprasidone (Higher Dose)	223
Overall Study	Received Study Treatment	Ziprasidone (Lower Dose)	216
Overall Study	Received Study Treatment	Placebo	217
Overall Study	COMPLETED	Ziprasidone (Higher Dose)	161
Overall Study	COMPLETED	Ziprasidone (Lower Dose)	168
Overall Study	COMPLETED	Placebo	179
Overall Study	NOT COMPLETED	Ziprasidone (Higher Dose)	71
Overall Study	NOT COMPLETED	Ziprasidone (Lower Dose)	58
Overall Study	NOT COMPLETED	Placebo	43

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00312494/flow